geïnactiveerd)
Sponsors
Litevax B.V., GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals, Leids Universitair Medisch Centrum (LUMC), GlaxoSmithKline Biologicals
Conditions
Healthy volunteers (prevention of influenza infection)HumanInfluenzahealthy individuals
Phase 1
A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and immunogenicity of one single administration of TETRALITE, a novel adjuvanted influenza vaccine, in healthy participants aged 18 to 50 years
CompletedCTIS2022-500681-98-00
Start: 2022-09-14End: 2023-05-17Target: 60Updated: 2022-12-05
A Phase 1/2, randomized, dose-finding/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults
CompletedCTIS2022-502308-66-00
Start: 2023-04-27End: 2024-07-02Target: 438Updated: 2024-05-27
Phase 2
A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.
CompletedCTIS2025-522278-35-00
End: 2025-09-10Target: 150Updated: 2025-09-09
A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older
Active, not recruitingCTIS2025-522599-97-00
Start: 2025-10-30Target: 168Updated: 2026-01-19